From the Department of Plastic and Reconstructive Surgery, Ohio State University Wexner Medical Center.
Vanguard Aesthetic Plastic Surgery.
Plast Reconstr Surg. 2024 Jan 1;153(1):154-163. doi: 10.1097/PRS.0000000000010692. Epub 2023 May 18.
Targeted muscle reinnervation (TMR) is an effective technique for the prevention and management of phantom limb pain (PLP) and residual limb pain (RLP) among amputees. The purpose of this study was to evaluate symptomatic neuroma recurrence and neuropathic pain outcomes between cohorts undergoing TMR at the time of amputation (ie, acute) versus TMR following symptomatic neuroma formation (ie, delayed).
A cross-sectional, retrospective chart review was conducted using patients undergoing TMR between 2015 and 2020. Symptomatic neuroma recurrence and surgical complications were collected. A subanalysis was conducted for patients who completed Patient-Reported Outcome Measurement Information System (PROMIS) pain intensity, interference, and behavior scales and an 11-point numeric rating scale (NRS) form.
A total of 105 limbs from 103 patients were identified, with 73 acute TMR limbs and 32 delayed TMR limbs. Nineteen percent of the delayed TMR group had symptomatic neuromas recur in the distribution of original TMR compared with 1% of the acute TMR group ( P < 0.05). Pain surveys were completed at final follow-up by 85% of patients in the acute TMR group and 69% of patients in the delayed TMR group. Of this subanalysis, acute TMR patients reported significantly lower PLP PROMIS pain interference ( P < 0.05), RLP PROMIS pain intensity ( P < 0.05), and RLP PROMIS pain interference ( P < 0.05) scores in comparison to the delayed group.
Patients who underwent acute TMR reported improved pain scores and a decreased rate of neuroma formation compared with TMR performed in a delayed fashion. These results highlight the promising role of TMR in the prevention of neuropathic pain and neuroma formation at the time of amputation.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
靶向肌肉神经再支配(TMR)是预防和治疗截肢患者幻肢痛(PLP)和残肢痛(RLP)的有效技术。本研究的目的是评估在截肢时(即急性)进行 TMR 与在出现症状性神经瘤后(即延迟)进行 TMR 的两组患者的症状性神经瘤复发和神经性疼痛结果。
使用 2015 年至 2020 年间接受 TMR 的患者进行了横断面、回顾性图表审查。收集了症状性神经瘤复发和手术并发症的资料。对完成患者报告的结局测量信息系统(PROMIS)疼痛强度、干扰和行为量表以及 11 点数字评定量表(NRS)表格的患者进行了亚分析。
共确定了 103 名患者的 105 个肢体,其中 73 个肢体进行了急性 TMR,32 个肢体进行了延迟 TMR。与急性 TMR 组的 1%相比,延迟 TMR 组有 19%的神经瘤在原 TMR 分布处复发(P < 0.05)。在急性 TMR 组中,有 85%的患者和延迟 TMR 组中 69%的患者完成了最终随访的疼痛调查。在亚分析中,急性 TMR 患者报告的 PLP PROMIS 疼痛干扰(P < 0.05)、RLP PROMIS 疼痛强度(P < 0.05)和 RLP PROMIS 疼痛干扰(P < 0.05)评分明显低于延迟组。
与延迟 TMR 相比,接受急性 TMR 的患者报告疼痛评分改善,神经瘤形成率降低。这些结果突出了 TMR 在预防截肢时神经性疼痛和神经瘤形成方面的有前景的作用。
临床问题/证据水平:治疗性,III 级。